Intravitreal aflibercept 2 mg regimen is linked with long-term visual acuity improvements in macular edema following CRVO.

Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD - Presented the first human data mapping ...